Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹28.18
0.27 (0.97%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹45 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹22.8+23.6%
52W High₹95-70.3%
Current Price
₹28.18
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹26.77
Upper Circuit₹29.59
Reference Price
₹28.18
Investment Checklist
Double Top on 1D (BREAKOUT CONFIRMED) — target ₹73.38
Falling Wedge on 1W — target ₹95.0
Trend: Price below most MAs — downtrend | Bearish MA stack (20<50<200)
20/50 Bearish Cross detected 5 day(s) ago
SuperTrend(10,3): Price below SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
51%
Trend
BEARISH
BEARISH
Price below most MAs — downtrend | Bearish MA stack (20<50<200)
EMA20
28.79
EMA50
29.52
EMA200
44.66
Price Action
CONSOLIDATION
NEUTRAL
Higher Highs4
Higher Lows5
Lower Highs5
Lower Lows4
Support & Resistance Levels
Resistance (Above)
₹28.46
₹29.56
₹31.48
₹33.05
₹35.40
Support (Below)
₹27.75
₹26.52
₹23.55
₹22.80
Volume Analysis
TrendDECREASING
Change-16.70%
Unusual VolumeNo
Recent MA Crossovers
20/50 Bearish Cross
5 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹27.90
3% Risk₹27.33
5% Risk₹26.77
7% Risk (Custom)
₹26.21Technical Levels
1x ATR (Volatility)₹26.91
2x ATR (Swing)₹25.64
3x ATR (Trend)₹24.37
Immediate Support₹27.75
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹70.4 Cr | ₹57.2 Cr | ₹49.3 Cr | ₹58.4 Cr |
| Net Profit | ₹5,94,000 | ₹-13.8 Cr | ₹-7.3 Cr | ₹-9.8 Cr |
| EPS | — | ₹-8.72 | ₹-4.64 | ₹-6.21 |
| Operating Profit | ₹6.6 Cr | ₹-4.5 Cr | ₹-2.8 Cr | ₹-1.3 Cr |
ROE
4.51%
ROCE
6.51%
Debt/Equity
0.65
Current Ratio
1.04
OPM
-2.26%
NPM
-16.85%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 17 Sept 2018 | Annual General Meeting | AGM |
| 21 Dec 2017 | Interim Dividend Re 0.50 Per Share | INTERIM_DIVIDEND |
| 18 Sept 2017 | Annual General Meeting | AGM |
| 22 Sept 2016 | Annual General Meeting (Book Closure Dates Revised) | AGM |
| 26 Aug 2015 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for MANGALAM
View All
positive
ET Markets - Industry 1d ago
AB Group reaffirms bet on Voda Idea with ₹4,730 Cr infusion
Vodafone Idea shareholders approved a ₹4,730-crore investment from the Aditya Birla Group via preferential allotment of warrants, increasing AB Group's stake to around 13%. Chairman Kumar Mangalam Birla stated the company's focus now shifts to execution across operations, customer service, and network expansion. This capital infusion will support capital expenditure and loan repayment, reinforcing Vi's financial health.
ABCAPITALABFRLABGSECABLBLABRELABSL10BANKABSLAMCABSLBANETFABSLLIQUIDABSLNN50ETABSLPSEAKCAPITBFINVESTBIRLACORPNBIRLAMONEYBSLGOLDETFBSLNIFTYBSLSENETFGCPCAPFOCUSGSEC10ABSLHEALTHYIDEAJMFINANCILMANGALAMMEDANTAMGELMOMENTUMNAHARCAPNIFTYQLITYSERVICESILVERTECHConstruction MaterialsConsumer Durables
positive
NDTV Profit 8d ago
'Impressive Even From the Outside': Kumar Mangalam Birla Hails Massive Reach Of RSS
Kumar Mangalam Birla addressing an RSS event in Nagpur.
BIRLACORPNMANGALAMMGELConstruction MaterialsFast Moving Consumer Goods
NEWS
neutral
Business Standard - Markets 11d ago
Mangalam Seeds consolidated net profit declines 63.02% in the March 2026 quarter
Sales decline 26.56% to Rs 15.87 crore
MANGALAMMGELFast Moving Consumer GoodsHealthcare